Randomized Phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma - Nayak, L; Molinaro, AM; Peters, K; Clarke, JL; Jordan, JT; Groot, J (Clin Cancer Res, 2021)